c4therapeutics.com (CCCC): Utang marang Ekuitas

Logo korporat perusahaan C4 Therapeutics Corp (CCCC)

The price history of C4 Therapeutics, Inc. (CCCC) demonstrates a standalone debt-to-equity ratio of 0.24. C4 Therapeutics, Inc. (CCCC) generates revenue by licensing an innovative platform designed to combat severe oncological diseases. Its technology stack leverages AI and robotics to rapidly identify protein degradation formulas. Meanwhile, the business faces a liquidity shortage and is depleting reserves on costly research.

CCCC: Rasio Total Utang marang Ekuitas C4 Therapeutics 04.07.2022 - 30.10.2026

Rincian metrik komprehensif lan analitis C4 Therapeutics Corp (CCCC)

- rega lan prakiraan konsensus rega:
Bagan rega C4 Therapeutics|CCCC - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar C4 Therapeutics|CCCC - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham C4 Therapeutics|CCCC - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku c4therapeutics.com|CCCC - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas C4 Therapeutics, Inc.|CCCC - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas C4 Therapeutics, Inc.|CCCC - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku C4 Therapeutics|CCCC - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan C4 Therapeutics|Indikator likuiditas cepet c4therapeutics.com
- informasi bathi lan kelipatan valuasi:
CCCC - Bathi pungkasan
Analisis fundamental perusahaan:C4 Therapeutics, CCCC
Barang utama C4 Therapeutics, Inc.

The analyst assesses the credit quality of C4 Therapeutics, Inc. (CCCC) through its liability structure. Planned laboratory utilization and partners' readiness for drug launches confirm the business's operational stability. This change in the debt-to-equity ratio measures the proportion of external debt relative to owner assets. A low ratio minimizes risks during rate hikes, creating a financial buffer. Investors should use this indicator to monitor leverage sustainability.

Pesaing C4 Therapeutics, Inc. (CCCC)

Utang marang Ekuitas Genmab|Utang marang Modal Exelixis Inc EXEL|Utang marang Ekuitas Nuvalent Corp (NUVL)|Kymera Corp - Rasio Utang marang Ekuitas|Total Utang marang Modal IDYA (IDEAYA Biosciences)|ELVN - Rasio Total Utang marang Ekuitas|ORIC - Utang marang Ekuitas|Utang marang Modal Relay Therapeutics Inc|Nurix Pharma (NRIX) - Utang marang Ekuitas|TYRA (Tyra Corp) - Utang marang Ekuitas|Utang marang Ekuitas Verastem, Inc.|Utang marang Modal monterosatx.com GLUE|Total Utang marang Modal CGEM|Immuneering Corp (IMRX) - Rasio Utang marang Modal|Black Diamond Therapeutics Inc. - Rasio Total Utang marang Ekuitas|Repare Therapeutics Inc (RPTX) - Utang marang Modal|PMVP: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi KPTI (Karyopharm Therapeutics)|PPCB (propanc.com) - Rasio Total Utang marang Ekuitas|BGMS: Utang Agregat marang Modal|AADI (Aadi Bioscience Inc) - Total Utang marang Modal|Total Utang marang Modal Aileron|Utang marang Ekuitas Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SWTX (SpringWorks Therapeutics, Inc.)